Dr Ashley Yocum speaks to ecancer about an update on the Beat AML master clinical trial.

She explains that the Beat AML master trial operates at 12 academic sites, enroling over 1600 patients.

It focusses on upfront trials using venetoclax and azacitidine for specific mutations, prioritising newly diagnosed patients with challenging mutations like TP53.

The initiative aims to expedite novel agents' introduction to enhance survival rates, especially for older AML patients.